Black Diamond Therapeutics Inc (BDTX)

[FACT-MASTER]

Interesting examples.

Interesting story behind Sunvozertinib:

https://www.evaluate.com/vantage/articles/events/conferences/asco-2023-dizal-heralds-super-tagrisso

Mobocertinib was also recently approved in China based on Phase 1/2 data:

https://www.takeda.com/newsroom/newsreleases/2023/takedas-exkivity-mobocertinib-receives-approval-from-the-nmpa-of-china-becoming-the-first-and-only-therapy-available-for-patients-with-egfr-exon20-insertion-nsclc/

These examples may serve some purpose, however we still need to wait on BDTX for the GBM phase 1 results which imo, go deeper down the mutational progression. This is where there could be some separation in the spectrum of therapy application, imo.